---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-25-000119"
form_type: "8-K"
ticker: null
cik: "0000910267"
company_name: "TITAN PHARMACEUTICALS INC"
filed_at: "2025-01-08T23:59:59+00:00"
generated_at: "2026-05-28T07:30:13.543047+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Titan Pharmaceuticals receives Nasdaq notice for failure to hold annual shareholder meeting; faces potential delisting

## Summary
- Received Nasdaq notice on Jan 3, 2025 for noncompliance with listing rules due to missing annual shareholder meeting within 12 months of fiscal year end.
- Has 45 days to submit a compliance plan; if accepted, Nasdaq may grant exception until June 30, 2025 to regain compliance.
- Failure to regain compliance could result in delisting of common stock from Nasdaq Capital Market.
- Company intends to schedule annual meeting and submit plan to regain compliance.

## SEC filing metadata
- accession: 0001829126-25-000119
- form_type: 8-K
- cik: 0000910267
- company_name: TITAN PHARMACEUTICALS INC
- filed_at: 2025-01-08T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/910267/000182912625000119/0001829126-25-000119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/910267/000182912625000119/titanpharma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-25-000119
- JSON: https://secwatch.observer/filing/0001829126-25-000119.json
- Plain text: https://secwatch.observer/filing/0001829126-25-000119.txt

## Key facts
- Listing & Compliance Notices
  TITAN PHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a), 5810(c)(2)(G)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: shareholders
  - Rules: 5620(a), 5810(c)(2)(G)
  source text: January 3, 2025, Titan Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications Staff of The Nasdaq Capital Market (“Nasdaq”) that the Company is in noncompliance with
  evidence_url: https://www.sec.gov/Archives/edgar/data/910267/000182912625000119/0001829126-25-000119-index.htm
- Listing & Compliance Notices
  TITAN PHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a), 5810(c)(2)(G)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: shareholders
  - Rules: 5620(a), 5810(c)(2)(G)
  source text: January 3, 2025, Titan Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications Staff of The Nasdaq Capital Market (“Nasdaq”) that the Company is in noncompliance with Listing Rules 5620(a) and 5810(c)(2)(G) as a result of its failure to hold an annual shareholder meeting within twelve months of the December 31, 2023 fiscal year end. The Notice has no immediate effect on the Company’s listing on the Nasdaq Capital Market. The Company now has 45 days to submit a plan to regain compliance. If that plan is accepted by Nasdaq, then the Company m
  evidence_url: https://www.sec.gov/Archives/edgar/data/910267/000182912625000119/0001829126-25-000119-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.